The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

The Role of Spinal Dopaminergic Transmission in the Analgesic Effect of Nefopam on Rat Inflammatory Pain

  • Kim, Do Yun (Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School) ;
  • Chae, Joo Wung (Center for Creative Biomedical Scientists, Chonnam National University Medical School) ;
  • Lim, Chang Hun (Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School) ;
  • Heo, Bong Ha (Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School) ;
  • Park, Keun Suk (Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School) ;
  • Lee, Hyung Gon (Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School) ;
  • Choi, Jeong Il (Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School) ;
  • Yoon, Myung Ha (Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School) ;
  • Kim, Woong Mo (Department of Anesthesiology and Pain Medicine, Chonnam National University Medical School)
  • Received : 2016.05.20
  • Accepted : 2016.06.14
  • Published : 2016.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Nefopam has been known as an inhibitor of the reuptake of monoamines, and the noradrenergic and/or serotonergic system has been focused on as a mechanism of its analgesic action. Here we investigated the role of the spinal dopaminergic neurotransmission in the antinociceptive effect of nefopam administered intravenously or intrathecally. Methods: The effects of intravenously and intrathecally administered nefopam were examined using the rat formalin test. Then we performed a microdialysis study to confirm the change of extracellular dopamine concentration in the spinal dorsal horn by nefopam. To determine whether the changes of dopamine level are associated with the nefopam analgesia, its mechanism was investigated pharmacologically via pretreatment with sulpiride, a dopaminergic D2 receptor antagonist. Results: When nefopam was administered intravenously the flinching responses in phase I of the formalin test were decreased, but not those in phase II of the formalin test were decreased. Intrathecally injected nefopam reduced the flinching responses in both phases of the formalin test in a dose dependent manner. Microdialysis study revealed a significant increase of the level of dopamine in the spinal cord by intrathecally administered nefopam (about 3.8 fold the baseline value) but not by that administered intravenously. The analgesic effects of intrathecally injected nefopam were not affected by pretreatment with sulpiride, and neither were those of the intravenous nefopam. Conclusions: Both the intravenously and intrathecally administered nefopam effectively relieved inflammatory pain in rats. Nefopam may act as an inhibitor of dopamine reuptake when delivered into the spinal cord. However, the analgesic mechanism of nefopam may not involve the dopaminergic transmission at the spinal level.

Keywords

References

  1. Kim KH, Abdi S. Rediscovery of nefopam for the treatment of neuropathic pain. Korean J Pain 2014; 27: 103-11. https://doi.org/10.3344/kjp.2014.27.2.103
  2. Esposito E, Romandini S, Merlo-Pich E, Mennini T, Samanin R. Evidence of the involvement of dopamine in the analgesic effect of nefopam. Eur J Pharmacol 1986; 128: 157-64. https://doi.org/10.1016/0014-2999(86)90762-4
  3. Fuller RW, Snoddy HD. Evaluation of nefopam as a monoamine uptake inhibitor in vivo in mice. Neuropharmacology 1993; 32: 995-9. https://doi.org/10.1016/0028-3908(93)90064-A
  4. Hunskaar S, Fasmer OB, Broch OJ, Hole K. Involvement of central serotonergic pathways in nefopam-induced antinociception. Eur J Pharmacol 1987; 138: 77-82. https://doi.org/10.1016/0014-2999(87)90339-6
  5. Rosland JH, Hole K. The effect of nefopam and its enantiomers on the uptake of 5-hydroxytryptamine, noradrenaline and dopamine in crude rat brain synaptosomal preparations. J Pharm Pharmacol 1990; 42: 437-8. https://doi.org/10.1111/j.2042-7158.1990.tb06587.x
  6. Vonvoigtlander PF, Lewis RA, Neff GL, Triezenberg HJ. Involvement of biogenic amines with the mechanisms of novel analgesics. Prog Neuropsychopharmacol Biol Psychiatry 1983; 7: 651-6. https://doi.org/10.1016/0278-5846(83)90040-4
  7. Gray AM, Nevinson MJ, Sewell RD. The involvement of opioidergic and noradrenergic mechanisms in nefopam antinociception. Eur J Pharmacol 1999; 365: 149-57. https://doi.org/10.1016/S0014-2999(98)00837-1
  8. Girard P, Coppé MC, Verniers D, Pansart Y, Gillardin JM. Role of catecholamines and serotonin receptor subtypes in nefopam-induced antinociception. Pharmacol Res 2006; 54: 195-202. https://doi.org/10.1016/j.phrs.2006.04.008
  9. Jeong SH, Heo BH, Park SH, Kim WM, Lee HG, Yoon MH, et al. Spinal noradrenergic modulation and the role of the alpha-2 receptor in the antinociceptive effect of intrathecal nefopam in the formalin test. Korean J Pain 2014; 27: 23-9. https://doi.org/10.3344/kjp.2014.27.1.23
  10. Yaksh TL, Rudy TA. Chronic catheterization of the spinal subarachnoid space. Physiol Behav 1976; 17: 1031-6. https://doi.org/10.1016/0031-9384(76)90029-9
  11. Cho SY, Park AR, Yoon MH, Lee HG, Kim WM, Choi JI. Antinociceptive effect of intrathecal nefopam and interaction with morphine in formalin-induced pain of rats. Korean J Pain 2013; 26: 14-20. https://doi.org/10.3344/kjp.2013.26.1.14
  12. Coderre TJ, Melzack R. The contribution of excitatory amino acids to central sensitization and persistent nociception after formalin-induced tissue injury. J Neurosci 1992; 12: 3665-70. https://doi.org/10.1523/JNEUROSCI.12-09-03665.1992
  13. Lee HG, Choi JI, Yoon MH, Obata H, Saito S, Kim WM. The antiallodynic effect of intrathecal tianeptine is exerted by increased serotonin and norepinephrine in the spinal dorsal horn. Neurosci Lett 2014; 583: 103-7. https://doi.org/10.1016/j.neulet.2014.09.022
  14. Smith DF, Glaser R, Gee A, Gjedde A. [11C]Nefopam as a potential PET tracer of serotonin reuptake sites. In: Quantification of brain function using PET. Edited by Myers R, Cunningham V, Bailey D, Jones T. San Diego (CA), Academic Press. 1996, pp 38-41.
  15. Millan MJ. Descending control of pain. Prog Neurobiol 2002; 66: 355-474. https://doi.org/10.1016/S0301-0082(02)00009-6
  16. Potvin S, Grignon S, Marchand S. Human evidence of a supra-spinal modulating role of dopamine on pain perception. Synapse 2009; 63: 390-402. https://doi.org/10.1002/syn.20616
  17. Franklin KB. Analgesia and abuse potential: an accidental association or a common substrate? Pharmacol Biochem Behav 1998; 59: 993-1002. https://doi.org/10.1016/S0091-3057(97)00535-2
  18. Altier N, Stewart J. The role of dopamine in the nucleus accumbens in analgesia. Life Sci 1999; 65: 2269-87. https://doi.org/10.1016/S0024-3205(99)00298-2
  19. Cobacho N, de la Calle JL, Paino CL. Dopaminergic modulation of neuropathic pain: analgesia in rats by a D2-type receptor agonist. Brain Res Bull 2014; 106: 62-71. https://doi.org/10.1016/j.brainresbull.2014.06.003
  20. Fairbanks CA. Spinal delivery of analgesics in experimental models of pain and analgesia. Adv Drug Deliv Rev 2003; 55: 1007-41. https://doi.org/10.1016/S0169-409X(03)00101-7
  21. Xu JJ, Walla BC, Diaz MF, Fuller GN, Gutstein HB. Intermittent lumbar puncture in rats: a novel method for the experimental study of opioid tolerance. Anesth Analg 2006; 103: 714-20. https://doi.org/10.1213/01.ane.0000226100.46866.ea
  22. Ohkubo Y, Nomura K, Yamaguchi I. Involvement of dopamine in the mechanism of action of FR64822, a novel non-opioid antinociceptive compound. Eur J Pharmacol 1991; 204: 121-5. https://doi.org/10.1016/0014-2999(91)90695-M
  23. Novelli A, Diaz-Trelles R, Groppetti A, Fernandez-Sanchez MT. Nefopam inhibits calcium influx, cGMP formation, and NMDA receptor-dependent neurotoxicity following activation of voltage sensitive calcium channels. Amino Acids 2005; 28: 183-91. https://doi.org/10.1007/s00726-005-0166-0
  24. Verleye M, Andre N, Heulard I, Gillardin JM. Nefopam blocks voltage-sensitive sodium channels and modulates glutamatergic transmission in rodents. Brain Res 2004; 1013: 249-55. https://doi.org/10.1016/j.brainres.2004.04.035

Cited by

  1. Effects of nefopam on catheter-related bladder discomfort in patients undergoing ureteroscopic litholapaxy vol.71, pp.3, 2018, https://doi.org/10.4097/kja.d.18.27113
  2. The Antiallodynic Effect of Nefopam on Vincristine-Induced Neuropathy in Mice vol.13, pp.None, 2016, https://doi.org/10.2147/jpr.s224478